Erratum: Thymoquinone poly(lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential (Biochem. Pharmacol. 79 (2010) (1640-164) DOI: 10.1016/j.bcp.2010.01.023);Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1640-1647

  Ravindran, Jayaraj ^a   Nair, Hareesh B ^b   Sung, Bokyung ^a   Prasad, Sahdeo ^a   Tekmal, Rajeshwar R ^b   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Apoptosis; Inflammation; Nanoparticles; NF B; Thymoquinone

Indexed keywords

CYCLIN D1; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; THYMOQUINONE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BIODEGRADABILITY; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 77950086914     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.11.011     Document Type: Erratum

References (45)

1. Gleeson M.P. Generation of a set of simple, interpretable ADMET rules of thumb. Journal of Medicinal Chemistry 2008, 51:817-834.
2. Newman D.J Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. Journal of Medicinal Chemistry 2008, 51:2589-2599.
3. 50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. Journal of Ayub Medical College Abbottabad 2008, 20:25-27.
4. Morikawa T., Xu F., Kashima Y., Matsuda H., Ninomiya K., Yoshikawa M. Novel dolabellane-type diterpene alkaloids with lipid metabolism promoting activities from the seeds of Nigella sativa. Organic Letters 2004, 6:869-872.
5. Badary O.A., Taha R.A., Gamal el-Din A.M., Abdel-Wahab M.H. Thymoquinone is a potent superoxide anion scavenger. Drug and Chemical Toxicology 2003, 26:87-98.
6. Badary O.A., Abd-Ellah M.F., El-Mahdy M.A., Salama S.A., Hamada F.M. Anticlastogenic activity of thymoquinone against benzo(a)pyrene in mice. Food and Chemical Toxicology 2007, 45:88-92.
7. Mansour M.A., Nagi M.N., El-Khatib A.S., Al-Bekairi A.M. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochemistry and Function 2002, 20:143-151.
8. Gali-Muhtasib H., Diab-Assaf M., Boltze C., Al-Hmaira J., Hartig R., Roessner A., et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. International Journal of Oncology 2004, 25:857-866.
9. Badary O.A., Al-Shabanah O.A., Nagi M.N., Al-Rikabi A.C., Elmazar M.M. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. European Journal of Cancer Prevention 1999, 8:435-440.
10. Badary O.A., Gamal El-Din A.M. Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. Cancer Detection and Prevention 2001, 25:362-368.
11. Gali-Muhtasib H.U., Abou Kheir W.G., Kheir L.A., Darwiche N., Crooks P.A. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anti-Cancer Drugs 2004, 15:389-399.
12. Gali-Muhtasib H., Ocker M., Kuester D., Krueger S., El-Hajj Z., Diestel A., et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. Journal of Cellular and Molecular Medicine 2008, 12:330-342.
13. Roepke M., Diestel A., Bajbouj K., Walluscheck D., Schonfeld P., Roessner A., et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biology & Therapy 2007, 6:160-169.
14. Shoieb A.M., Elgayyar M., Dudrick P.S., Bell J.L., Tithof P.K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. International Journal of Oncology 2003, 22:107-113.
15. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Wani A.A. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. International Journal of Cancer 2005, 117:409-417.
16. Tan M., Norwood A., May M., Tucci M., Benghuzzi H. Effects of (-)epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomedical Sciences Instrumentation 2006, 42:363-371.
17. Worthen D.R., Ghosheh O.A., Crooks P.A. The in vitro anti-tumor activity of some crude and purified components of blackseed Nigella sativa L. Anticancer Research 1998, 18:1527-1532.
18. Sethi G., Ahn K.S., Aggarwal B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Molecular Cancer Research 2008, 6:1059-1070.
19. Yi T., Cho S.G., Yi Z., Pang X., Rodriguez M., Wang Y., et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Molecular Cancer Therapeutics 2008, 7:1789-1796.
20. Kaseb A.O., Chinnakannu K., Chen D., Sivanandam A., Tejwani S., Menon M., et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Research 2007, 67:7782-7788.
21. Banerjee S., Kaseb A.O., Wang Z., Kong D., Mohammad M., Padhye S., et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Research 2009, 69:5575-5583.
22. van Vlerken L.E., Amiji M.M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opinion on Drug Delivery 2006, 3:205-216.
23. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. Journal of Controlled Release 2005, 109:169-188.
24. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research 2007, 24:1-16.
25. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews 2002, 54:631-651.
26. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research 2008, 14:1310-1316.
27. Ankola D.D., Viswanad B., Bhardwaj V., Ramarao P., Kumar M.N. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?. European Journal of Pharmaceutics and Biopharmaceutics 2007, 67:361-369.
28. Hariharan S., Bhardwaj V., Bala I., Sitterberg J., Bakowsky U., Ravi Kumar M.N. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharmaceutical Research 2006, 23:184-195.
29. Bala I., Bhardwaj V., Hariharan S., Kumar M.N. Analytical methods for assay of ellagic acid and its solubility studies. Journal of Pharmaceutical and Biomedical Analysis 2006, 40:206-210.
30. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. Journal of Nanobiotechnology 2007, 5:3.
31. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. Journal of Controlled Release 2003, 86:33-48.
32. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clinical Cancer Research 1999, 5:83-94.
33. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology 2005, 23:7794-7803.
34. Yamamoto K., Arakawa T., Ueda N., Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. The Journal of Biological Chemistry 1995, 270:31315-31320.
35. Aggarwal B.B., Takada Y., Oommen O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opinion on Investigational Drugs 2004, 13:1327-1338.
36. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Medicine 2002, 8:751-755.
37. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:13549-13554.
38. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:932-936.
39. von Maltzahn G., Ren Y., Park J.H., Min D.H., Kotamraju V.R., Jayakumar J., et al. In vivo tumor cell targeting with " click" nanoparticles. Bioconjugate Chemistry 2008, 19:1570-1578.
40. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochemical Pharmacology 2010;79:330-8.
41. Wu T.H., Yen F.L., Lin L.T., Tsai T.R., Lin C.C., Cham T.M. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. International Journal of Pharmaceutics 2008, 346:160-168.
42. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. Journal of Medicinal Chemistry 2003, 46:190-193.
43. Kim D.W., Kwon J.S., Kim Y.G., Kim M.S., Lee G.S., Youn T.J., et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004, 109:1558-1563.
44. Gupta V., Aseh A., Rios C.N., Aggarwal B.B., Mathur A.B. Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. International Journal of Nanomedicine 2009, 4:115-122.
45. Adhami V.M., Siddiqui I.A., Sarfaraz S., Khwaja S.I., Hafeez B.B., Ahmad N., et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clinical Cancer Research 2009, 15:1947-1953.